According to DevelInsight analysis, the estimated total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal ...

EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Zai Lab's repotrectinib label expansion accepted in China for treating advanced solid tumors with NTRK gene fusion.

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...